Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FMEG3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $85,107
Award facts
- Contract value 100% obligated
- $85,106.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $85.1K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 capsules of Xtandi 40 mg. The contract, issued on January 22, 2026, with an ultimate completion date of January 23, 2026, represents a firm fixed-price delivery order with no set-aside designation. This award falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support recurring pharmaceutical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as a critical supplier within the military medical supply chain, with a single-award IDC ceiling value of $500M under the PPV-G GEN V contract awarded in November 2025 and extending through December 2036. The company's product portfolio spans branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, including oncology treatments such as Xtandi. With no identified subcontractors on this award and consistent delivery order performance across multiple therapeutic categories, DMS Pharmaceutical Group serves as one of multiple regional prime vendors positioned to fulfill the specialized pharmaceutical requirements of Department of Defense military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FMEG3?
SPE2DR26FMEG3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FMEG3 worth?
The government has obligated $85,107 on SPE2DR26FMEG3.
Is contract SPE2DR26FMEG3 an order under another contract?
Yes. SPE2DR26FMEG3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEG3 competed?
The extent of competition for SPE2DR26FMEG3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award